Cargando…

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

This review summarizes recent development in synthetic drugs and biologics targeting intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current perspective and potential leads for the field. Compared to biologics, small molecule inhibitors (SMIs) readily penetrate cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Kuen Kuen, Wong, Siew Heng, Cheah, Peh Yean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954350/ https://www.ncbi.nlm.nih.gov/pubmed/36831298 http://dx.doi.org/10.3390/cells12040631

Ejemplares similares

KRAS mutation‐independent downregulation of MAPK/PI3K signaling in colorectal cancer
por: Lam, Kuen Kuen, et al.
Publicado: (2022)

KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
por: El Osta, Badi
Publicado: (2023)

Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”
por: Nagasaka, Misako, et al.
Publicado: (2023)

Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021)

Targeting STATs for cancer therapy: “Undruggable” no more
por: Frank, David A.
Publicado: (2012)

Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021)

Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead
por: Li, Hui-yu, et al.
Publicado: (2021)

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
por: Lu, Yuqing, et al.
Publicado: (2023)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

Targeting the “undruggable” RAS - new strategies - new hope?
por: Mörchen, Britta, et al.
Publicado: (2019)

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
por: Xie, Xin, et al.
Publicado: (2023)

Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?
por: Shillingford, Shanelle R., et al.
Publicado: (2023)

Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
por: Hargreaves, David, et al.
Publicado: (2023)

Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021)

Targeting the undruggable: an interview with Leila Akkari on fighting cancer by rewiring cells
Publicado: (2021)

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome
por: Lee, Kristi Y., et al.
Publicado: (2022)

Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors
por: Dai, Mengyuan, et al.
Publicado: (2022)

Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets
por: Moon, Seonghyeon, et al.
Publicado: (2018)

A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
por: Park, Woo-Jung, et al.
Publicado: (2023)

Rational antibody design for undruggable targets using kinetically controlled biomolecular probes
por: Trkulja, Carolina L., et al.
Publicado: (2021)

Targeting undruggable carbohydrate recognition sites through focused fragment library design
por: Shanina, Elena, et al.
Publicado: (2022)

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS
por: Pang, Jia Meng, et al.
Publicado: (2023)

Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs
por: Bartolucci, Damiano, et al.
Publicado: (2022)

Drugging the undruggables: exploring the ubiquitin system for drug development
por: Huang, Xiaodong, et al.
Publicado: (2016)

Drugging the “undruggable” DNA-binding domain of STAT3
por: Zhang, Jian-Ting, et al.
Publicado: (2016)

Drugging the undruggable: Ross Cagan interviews Kevan Shokat
por: Cagan, Ross, et al.
Publicado: (2022)

Drugging the Undruggable Trypanosoma brucei Monothiol Glutaredoxin 1
por: Favaro, Annagiulia, et al.
Publicado: (2023)

ATNC: Versatile Nanobody Chimeras for Autophagic Degradation of Intracellular Unligandable and Undruggable Proteins
por: He, Huiping, et al.
Publicado: (2023)

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
por: Knott, Maximilian M. L., et al.
Publicado: (2020)

The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting
por: Casalino, Laura, et al.
Publicado: (2022)

The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe
por: Epstein, Richard J.
Publicado: (2013)

Big data and artificial intelligence discover novel drugs targeting proteins without 3D structure and overcome the undruggable targets
por: He, Huiqin, et al.
Publicado: (2020)

Targeting KRAS: The Elephant in the Room of Epithelial Cancers
por: Merz, Valeria, et al.
Publicado: (2021)

Prediction of Druggable Allosteric Sites of Undruggable Multidrug Resistance Efflux Pump P. Gingivalis Proteins
por: Yadalam, Pradeep Kumar, et al.
Publicado: (2023)

Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fv0dli0vomeus6eu84jk5358fr